ZimVie announced it has received FDA clearance for its Vital Spinal Fixation System including instruments for use with Brainlab Spine & Trauma Navigation. This follows the execution of the companies’ Development Cooperation Agreement, announced in March 2023, to achieve compatibility between ZimVie’s Vital and Virage systems and Brainlab Spine & Trauma Navigation, which helps surgeons plan and execute spinal procedures, accurately place pedicle screws, and minimize radiation exposure. “This is a positive milestone for both teams and the first of what we hope will be many FDA clearances for compatibility. The strong collaboration between our organizations resulted in an expedited project timeline,” said Rebecca Whitney, Global President of ZimVie Spine. “We have been focused on expanding our portfolio with enabling technologies to drive greater adoption, and I am excited to see the team advance toward the launch.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZIMV:
- ZimVie initiated with a Hold at Needham
- ZimVie Reports Third Quarter 2023 Financial Results and Provides Update to Annual Guidance
- ZimVie announces first U.S. surgery with 4.5mm Mobi-C Cervical Disc
- ZimVie announces over 2,000 children have received The Tether VBT
- ZimVie Announces the Launch of Azure™ Multi-Platform Product Solutions